The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Total Raised

$46M

Investors Count

12

Deal Terms

2

Elitra Pharmaceuticals Funding, Elitra Pharmaceuticals Valuation & Elitra Pharmaceuticals Revenue

5 Fundings

Elitra Pharmaceuticals's latest funding round was a Acquired for on May 17, 2004.

Elitra Pharmaceuticals's valuation in October 1998 was $6.93M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

5/17/2004

Acquired

0

FY undefined

8/21/2000

Series C

$99M

0

FY undefined

0

4/1/2000

Unattributed

$99M

0

FY undefined

0

7/1/1999

Series B

$99M

0

FY undefined

0

10/1/1998

Series A

$99M

$6.93M

0

FY undefined

0

Date

5/17/2004

8/21/2000

4/1/2000

7/1/1999

10/1/1998

Round

Acquired

Series C

Unattributed

Series B

Series A

Amount

$99M

$99M

$99M

$99M

Investors

Valuation

$6.93M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

0

0

0

0

Elitra Pharmaceuticals Deal Terms

2 Deal Terms

Elitra Pharmaceuticals's deal structure is available for 2 funding rounds, including their Series B from July 01, 1999.

Round

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Elitra Pharmaceuticals Investors

12 Investors

Elitra Pharmaceuticals has 12 investors. Merck & Co. invested in Elitra Pharmaceuticals's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

5/17/2004

5/17/2004

1
Acquired

Corporation

New Jersey

8/21/2000

8/21/2000

1
Series C

Venture Capital

Minnesota

8/21/2000

8/21/2000

1
Series C

Venture Capital

California

00/00/0000

00/00/0000

Incyte

Subscribe to see more

Corporation

Delaware

00/00/0000

00/00/0000

Cooper Hill Partners

Subscribe to see more

Hedge Fund

New York

First funding

5/17/2004

8/21/2000

8/21/2000

00/00/0000

00/00/0000

Last Funding

5/17/2004

8/21/2000

8/21/2000

00/00/0000

00/00/0000

Investor

Incyte

Cooper Hill Partners

Rounds

1
Acquired
1
Series C
1
Series C

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Venture Capital

Venture Capital

Corporation

Hedge Fund

Location

New Jersey

Minnesota

California

Delaware

New York

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

P
Plexigen

Plexigen is developing a 3-D biochip to enhance the capacity, efficiency, accuracy, and automation of gene screening. The technology was originally developed at North Carolina State University.

E
EcoAlert

Plymouth Marine Laboratory (PML) has been conducting research into marine organisms for more than 20 years funded by NERC. EcoAlert Ltd has been formed by PML's wholly owned technology transfer company, Plymouth Marine Applications Ltd (PMA), to commercialise a bioassay technique arising from this work. The Company has exclusive rights to ECOBOX, a portable bioassay kits for in-situ analysis of marine, estuarine and freshwater aquatic environments.

Van Andel Institute Logo
Van Andel Institute

VARi has several research programs in basic sciences that will improve our understanding of the cancer process, including programs rich in functional genomics. They have a long-term commitment to the development of programs that facilitate the translation of these basic science discoveries into therapeutic strategies for attacking cancer and thus improving human health.

M
Matrix Sensors

Matrix Sensors aims to democratize air quality sensors for a cleaner, healthier, and safer world.

O
Occam Research

The RDSP was created to help investigators identify funding opportunities and provide assistance to applicants. The RDSP staff work to stimulate research in cancer CAM and design activities that will develop the foundation of the science in cancer CAM research. RDSP programs include a series of Expert Panels on Research Methodologies in Cancer, an Invited Speakers Series, and technical assistance to help investigators prepare grant applications in cancer CAM.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.